Clinical trials located in

Pierre Benite Cedex

Pierre Benite Cedex city is located in France. Currently, 3 clinical trials are being conducted in this city.

  • CT-EU-00116695

    Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Exploring ELVN-001 in a trial for chronic myeloid leukemia safety and efficacy

    The study being described is a Phase 1 clinical trial of a drug named ELVN-001, which is being tested for the treatment of chronic myeloid leukemia (CML). This trial aims to evaluate the safety and effectiveness of ELVN-001, particularly its ability to be tolerated by patients and its impact on the disease. The study is designed to first determine the most suitable dose of ELVN-001 and then observe its effects on patients who have either relapsed from or are intolerant to standard treatments. The trial will involve administering the drug and monitoring patients for any reactions or improvements in their condition.

    • ELVN-001
  • Exploring the Safety and Dosage of JNJ-88549968 for CALR-Mutated Blood Disorders

    A study is being introduced that focuses on a new treatment option, JNJ-88549968, for patients with Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms. The aim is to explore the safety and effectiveness of JNJ-88549968 and to determine the best dose and schedule for treatment.

    In the first part of the study, the dose of JNJ-88549968 will be gradually increased to identify the safest and most effective level. Close monitoring for any side effects, particularly those that are severe or unexpected, will be conducted to ensure the highest level of safety for participants.

    The second part of the study will continue to evaluate the safety of JNJ-88549968 at the recommended dose. Attention will be given to how participants respond to the treatment and any side effects they experience. The severity of any side effects will be carefully graded to better understand the treatment’s impact.

    This study represents a significant advancement in the search for new treatments for Myeloproliferative Neoplasms. Participation will contribute valuable information that could potentially improve the lives of others with these conditions in the future.

    • JNJ-88549968

See more clinical trials in other cities in France: